1982 …2018
If you made any changes in Pure these will be visible here soon.

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 1982 2018

Cystathionine β -Synthase in Physiology and Cancer

Zhu, H., Blake, S., Chan, K. T., Pearson, R. B. & Kang, J., 28 Jun 2018, In : BioMed Research International. 2018, 11 p., 3205125.

Research output: Contribution to journalReview ArticleResearchpeer-review

Open Access
File

How the evolution of multicellularity set the stage for cancer

Trigos, A. S., Pearson, R. B., Papenfuss, A. T. & Goode, D. L., 16 Jan 2018, In : British Journal of Cancer. 118, 2, p. 145-152 8 p.

Research output: Contribution to journalReview ArticleResearchpeer-review

Open Access
File

Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma

Kondrashova, O., Topp, M., Nesic, K., Lieschke, E., Ho, G. Y., Harrell, M. I., Zapparoli, G. V., Hadley, A., Holian, R., Boehm, E., Heong, V., Sanij, E., Pearson, R. B., Krais, J. J., Johnson, N., McNally, O., Ananda, S., Alsop, K., Hutt, K. J., Kaufmann, S. H. & 11 othersLin, K. K., Harding, T. C., Traficante, N., Australian Ovarian Cancer Study (AOCS), deFazio, A., McNeish, I. A., Bowtell, D. D., Swisher, E. M., Dobrovic, A., Wakefield, M. J. & Scott, C. L., 1 Dec 2018, In : Nature Communications. 9, 1, 16 p., 3970.

Research output: Contribution to journalArticleResearchpeer-review

Open Access
File

Palbociclib synergizes with BRAF and MEK inhibitors in treatment naïve melanoma but not after the development of BRAF inhibitor resistance

Martin, C. A., Cullinane, C., Kirby, L., Abuhammad, S., Lelliott, E. J., Waldeck, K., Young, R. J., Brajanovski, N., Cameron, D. P., Walker, R., Sanij, E., Poortinga, G., Hannan, R. D., Pearson, R. B., Hicks, R. J., McArthur, G. A. & Sheppard, K. E., 15 May 2018, In : International Journal of Cancer. 142, 10, p. 2139-2152 14 p.

Research output: Contribution to journalArticleResearchpeer-review

Patient-derived Models of Abiraterone- and Enzalutamide-resistant Prostate Cancer Reveal Sensitivity to Ribosome-directed Therapy

Lawrence, M. G., Obinata, D., Sandhu, S., Selth, L. A., Wong, S. Q., Porter, L. H., Lister, N., Pook, D., Pezaro, C. J., Goode, D. L., Rebello, R. J., Clark, A. K., Papargiris, M., Van Gramberg, J., Hanson, A. R., Banks, P., Wang, H., Niranjan, B., Keerthikumar, S., Hedwards, S. & 32 othersHuglo, A., Yang, R., Henzler, C., Li, Y., Lopez-Campos, F., Castro, E., Toivanen, R., Azad, A., Bolton, D., Goad, J., Grummet, J., Harewood, L., Kourambas, J., Lawrentschuk, N., Moon, D., Murphy, D. G., Sengupta, S., Snow, R., Thorne, H., Mitchell, C., Pedersen, J., Clouston, D., Norden, S., Ryan, A., Dehm, S. M., Tilley, W. D., Pearson, R. B., Hannan, R. D., Frydenberg, M., Furic, L., Taylor, R. A. & Risbridger, G. P., 1 Nov 2018, In : European Urology. 74, 5, p. 562-572 11 p.

Research output: Contribution to journalArticleResearchpeer-review